Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy
Authors
Keywords
-
Journal
ONCOGENE
Volume 33, Issue 43, Pages 5053-5064
Publisher
Springer Nature
Online
2013-11-26
DOI
10.1038/onc.2013.497
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Antiangiogenic Agents, Chemotherapy, and the Treatment of Metastatic Transitional Cell Carcinoma
- (2013) Nicholas J. Vogelzang JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer
- (2013) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences
- (2013) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma as a model tumour for immuno-oncology
- (2012) M. Maio ANNALS OF ONCOLOGY
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
- (2012) Nadeem A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Castration-resistant prostate cancer: systemic therapy in 2012
- (2012) FC Maluf et al. Clinics
- Combining immunological and androgen-directed approaches
- (2012) Emmanuel S. Antonarakis et al. CURRENT OPINION IN ONCOLOGY
- Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population-based analysis
- (2012) Firas Abdollah et al. INTERNATIONAL JOURNAL OF UROLOGY
- Immunohistochemistry in the era of personalised medicine
- (2012) Clare Margaret McCourt et al. JOURNAL OF CLINICAL PATHOLOGY
- Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures
- (2012) Xuan Huang et al. Journal of Hematology & Oncology
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
- (2012) Li Shen et al. PLoS One
- The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development
- (2012) Paul G Corn Cancer Management and Research
- Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
- (2012) Susan R. Slovin Frontiers in Oncology
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- How to improve the immunogenicity of chemotherapy and radiotherapy
- (2011) Yuting Ma et al. CANCER AND METASTASIS REVIEWS
- Circulating Tumors Cells as Biomarkers
- (2011) Daniel C. Danila et al. CANCER JOURNAL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
- (2011) F. Dayyani et al. JNCI-Journal of the National Cancer Institute
- Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
- (2011) M. Marin-Aguilera et al. MOLECULAR CANCER THERAPEUTICS
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Contribution of the immune system to the chemotherapeutic response
- (2011) Alison M. McDonnell et al. Seminars in Immunopathology
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) A. Horwich et al. ANNALS OF ONCOLOGY
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
- (2010) K. N. Kodumudi et al. CLINICAL CANCER RESEARCH
- Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
- (2010) Michael Dickinson et al. INVESTIGATIONAL NEW DRUGS
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
- (2010) Axel Hoos et al. SEMINARS IN ONCOLOGY
- Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence
- (2010) Francis Lee et al. Therapeutic Advances in Medical Oncology
- Increased expression of class III β-tubulin in castration-resistant human prostate cancer
- (2009) S Terry et al. BRITISH JOURNAL OF CANCER
- Invariant Natural Killer T Cells Regulate Breast Cancer Response to Radiation and CTLA-4 Blockade
- (2009) K. A. Pilones et al. CLINICAL CANCER RESEARCH
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Cyclophosphamide Unmasks an Antimetastatic Effect of Local Tumor Cryoablation
- (2009) M. Y. Levy et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacy
- (2009) Kenji Kuroda et al. PROSTATE
- Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer
- (2008) Robert W. Ross et al. CANCER
- Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse
- (2008) Alain P. Vicari et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement
- (2008) C. T. Garnett et al. CLINICAL CANCER RESEARCH
- Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy
- (2008) R. A. Madan et al. CLINICAL CANCER RESEARCH
- The anticancer immune response: indispensable for therapeutic success?
- (2008) Laurence Zitvogel et al. JOURNAL OF CLINICAL INVESTIGATION
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiotherapy augments the immune response to prostate cancer in a time-dependent manner
- (2008) Timothy J. Harris et al. PROSTATE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More